Clinical Research Papers:
Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Metrics: PDF 799 views | HTML 1285 views | ?
Shuai Wang1, Zhe Yang2 and Zhou Wang1
1 Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, People’s Republic of China
2 Department of Oncology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, People’s Republic of China
Zhou Wang, email:
Keywords: lung cancer, angiogenesis inhibitors, VEGFR, TKIs, meta analysis
Received: March 14, 2015 Accepted: June 05, 2015 Published: June 19, 2015
Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) might be new therapeutic strategies for advanced non-small cell lung cancer (NSCLC). Here a total of 12,520 patients from 23 randomized controlled trials (RCTs) were enrolled to evaluate the efficacy and safety of VEGFR-TKIs quantitatively in advanced NSCLC. Compared with non-VEGFR-TKIs, VEGFR-TKIs regimen significantly improved progression-free survival (PFS) [hazard ratio (HR): 0.839, 95% confidence interval (CI): 0.805-0.874, P < 0.001], objective response rates (ORR) [relative risk (RR): 1.374, 95% CI: 1.193-1.583, P < 0.001] and disease control rates (DCR) (RR: 1.113, 95% CI: 1.027-1.206, P = 0.009), but not overall survival (OS) (HR: 0.960, 95% CI: 0.921-1.002, P = 0.060) for NSCLC patients. The RR of all-grade neutropenia, thrombocytopenia, hypertension, hemorrhage, fatigue, anorexia, stomatitis, diarrhea, rash, hand-foot skin reaction (HFSR) were increased in patients received VEGFR-TKIs. As for high-grade (≥ 3) adverse events (AEs), VEGFR-TKIs were associated with higher RR of neutropenia, thrombocytopenia, hypertension, fatigue, stomatitis, diarrhea, rash and HFSR. This study demonstrates VEGFR-TKIs improve PFS, ORR and DCR, but not OS in advanced NSCLC patients. VEGFR-TKIs induce more frequent and serious AEs compared with control therapies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.